|
gptkbp:instanceOf
|
drug
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
Tagrisso
|
|
gptkbp:chemicalFormula
|
C18H21N7O3S
|
|
gptkbp:clinicalTrials
|
Phase III
AURA1
AURA2
AURA3
FLAURA
|
|
gptkbp:contraindication
|
hypersensitivity to osimertinib
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:dosageForm
|
80 mg once daily
|
|
gptkbp:endOfLife
|
48 hours
|
|
gptkbp:firstAwarded
|
gptkb:EGFR_mutation-positive_NSCLC
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:hasPopulation
|
adults
pediatric patients
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Osimertinib
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
CYP3A4 inducers
|
|
gptkbp:isATypeOf
|
1421373-65-0
|
|
gptkbp:issuedBy
|
oral tablet
|
|
gptkbp:mandates
|
gptkb:EGFR_T790M_mutation-positive_NSCLC
|
|
gptkbp:marketedAs
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:nutritionalValue
|
liver
|
|
gptkbp:offers
|
varies by country
|
|
gptkbp:operates_in
|
L01XE30
|
|
gptkbp:patentExpiration
|
2026
|
|
gptkbp:patentStatus
|
patented
|
|
gptkbp:releaseYear
|
2015
|
|
gptkbp:researchFocus
|
targeted therapy
precision medicine
lung cancer treatment
molecularly targeted drugs
|
|
gptkbp:route
|
oral
|
|
gptkbp:safetyFeatures
|
hepatotoxicity
interstitial lung disease
cardiac events
QT prolongation
|
|
gptkbp:servesLine
|
T790M mutation-positive NSCLC
|
|
gptkbp:sideEffect
|
fatigue
nausea
diarrhea
rash
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:EGFR_mutations
|
|
gptkbp:triggerType
|
EGFR_tyrosine_kinase_inhibitor
|
|
gptkbp:usedFor
|
non-small cell lung cancer
|
|
gptkbp:waterManagement
|
urine
|